Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
U333275-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $528.90 | |
U333275-250mg | 250mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $2,380.90 | |
U333275-1g | 1g | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $8,569.90 |
PDE5A (phosphodiesterase 5) inhibitor.
Synonyms | Udenafil|268203-93-6|Zydena|DA-8159|L5IB4XLY36|3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide|CID 6918523|3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo(4,3-d)pyrimidin-5-y |
---|---|
Specifications & Purity | 98% |
Storage Temp | Store at 2-8°C |
Shipped In | Wet ice |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Phosphodiesterase 5A inhibitor |
Product Description | Udenafil is an oral phosphodiesterase 5 inhibitor. |
pKa | pKₐ: 3.5 (Predicted) |
---|---|
ALogP | 3 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide |
---|---|
INCHI | InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32) |
InChi Key | IYFNEFQTYQPVOC-UHFFFAOYSA-N |
Canonical SMILES | CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)NCCC4CCCN4C)OCCC)C |
Isomeric SMILES | CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)NCCC4CCCN4C)OCCC)C |
PubChem CID | 135413547 |
Molecular Weight | 516.66 |
PubChem CID | 135413547 |
---|---|
CAS Registry No. | 268203-93-6 |
ChEMBL Ligand | CHEMBL2103849 |
DrugBank Ligand | DB06267 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
B2426260 | Certificate of Analysis | Jun 20, 2022 | U333275 |
H2224316 | Certificate of Analysis | Jun 20, 2022 | U333275 |
H2224361 | Certificate of Analysis | Jun 20, 2022 | U333275 |
H2224541 | Certificate of Analysis | Jun 20, 2022 | U333275 |
Solubility | Soluble in chloroform, and methanol. |
---|---|
Melt Point(°C) | 154.0-155.0° C |
1. Oh TY, Kang KK, Ahn BO, Yoo M, Kim WB. (2000) Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159.. Arch Pharm Res, 23 (5): (471-6). [PMID:11059826] |
2. Shim HJ, Lee EJ, Kim SH, Kim SH, Yoo M, Kwon JW, Kim WB, Lee HS, Lee MG. (2000) Pharmacokinetics, stability, and blood partition of DA-8159, a new phosphodiesterase V inhibitor.. Res Commun Mol Pathol Pharmacol, 108 (3-4): (275-86). [PMID:11913718] |
3. Ahn BO, Kang KK, Ahn GJ, Kwon JW, Kim WB, Kang KS, Lee YS. (2003) Efficacy of DA-8159, a new PDE5 inhibitor, for inducing penile erection in rabbits with acute spinal cord injury.. Int J Impot Res, 15 (6): (405-11). [PMID:14671658] |